Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients With Major Depressive Disorder

NCT03352453 is registered in ClinicalTrials.gov with Naurex, Inc, an affiliate of Allergan plc as lead sponsor.

NCT NCT03352453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03352453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients With Major Depressive Disorder
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Phase
Phase 2
Overall status
Terminated
Start date
December 15, 2017
Completion date
June 21, 2019
Enrollment
138 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major